



# Proteomics comparison between mass-like and non-mass-like breast lesions

Shi-Yu Li<sup>1</sup>, Bo Wang<sup>1</sup>, Ying Jiang<sup>1</sup>, Junkang Li<sup>1</sup>, Gang Liu<sup>2</sup>, Zhi-Li Wang<sup>1</sup>

<sup>1</sup>Department of Ultrasound, The First Medical Center of PLA General Hospital, Beijing, China; <sup>2</sup>Department of Radiology, The First Medical Center of PLA General Hospital, Beijing, China

**Contributions:** (I) Conception and design: SY Li, ZL Wang; (II) Administrative support: G Liu, ZL Wang; (III) Provision of study materials or patients: SY Li, B Wang; (IV) Collection and assembly of data: Y Jiang, J Li; (V) Data analysis and interpretation: SY Li, J Li; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Gang Liu. Department of Radiology, The First Medical Center of PLA General Hospital, 28 Fuxing Road, Beijing 100853, China. Email: lgwzl@126.com; Zhi-Li Wang, MD. Department of Ultrasound, The First Medical Center of PLA General Hospital, 28 Fuxing Road, Beijing 100853, China. Email: wzllg@sina.com.

**Background:** The proteomic differences between mass-like (ML) breast lesions and non-mass-like (NML) breast lesions were compared to explore the formation mechanism of NML ultrasonic morphological characteristics.

**Methods:** From January to August 2021, tissue samples were collected from 10 patients with malignant ML (MML), 10 patients with malignant NML (MNML), 10 patients with benign ML (BML), and seven patients with benign NML (BNML). The proteomic differences between the BML and BNML groups and the MML and MNML groups were compared by data-independent acquisition (DIA) quantitative mass spectrometry. The differentially expressed proteins were analyzed by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) networks analyses.

**Results:** We identified a total of 623 significantly differentially expressed proteins in the MML/MNML group, and 167 significantly differentially expressed proteins in the BML/BNML group, with relative ratios >1.2 or <-0.83. The up-regulated differential proteins were more abundant in the tumor necrosis factor (TNF) signaling pathway in both the MML/MNML and BML/BNML groups, suggesting that the TNF signaling pathway may be related to the ultrasonic morphological characteristics of breast lesions. Dual specificity mitogen-activated protein kinase 3 (MP2K3), a protein factor in the TNF signaling pathway, exhibited significant upregulation in both the malignant and BML groups.

**Conclusions:** The TNF signaling pathway may be associated with the ultrasonic morphological characteristics of breast lesions. MP2K3 is the up-regulated differential expression protein in the MML/MNML and BML/BNML groups, which may be related to the ultrasonic morphological characteristics of breast lesions.

**Keywords:** Breast lesions; non-mass breast lesions; proteomics

Submitted Dec 16, 2022. Accepted for publication Jan 11, 2023. Published online Jan 31, 2023.

doi: 10.21037/atm-22-6655

View this article at: <https://dx.doi.org/10.21037/atm-22-6655>

## Introduction

Breast cancer is the most common malignant tumor and the second most common cause of cancer-related death in women (1). Although the overall 5-year survival rate has improved, at least 20 % of patients continue to develop

metastatic disease, with a poor prognosis (2). At present, histopathological factors including tumor size, grade, lymph node status, hormone, and human epidermal growth factor receptor-2 (HER2) receptor status can be used to guide breast cancer treatment and predict prognosis (3). However,

the prognosis of many patients with histologically similar tumors may be very different, so additional biomarkers for prediction, diagnosis, and prognosis are still needed.

Since the results of conventional ultrasound (US) are not affected by breast density, US has become a routine imaging tool for breast detection and diagnosis (4). According to the Breast Imaging Reporting and Data System (BI-RADS)-US released by the American College of Radiology, mass-like (ML) lesions are those that exhibit a mass effect on two different planes (5). However, 5–9 % of breast lesions present as localized asymmetric focal low echo areas on two vertical planes with no apparent margin or shape, and therefore do not meet the strict “mass” criteria defined by BI-RADS (6). Radiologists refer to these as non-mass-like (NML) lesions, which correspond to non-mass enhancement on breast magnetic resonance imaging (7).

The histological presentation of NML breast cancer tends to be ductal component-dominant ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (8,9). Previous studies have shown that the ultrasonographic appearance of breast cancer as mass or non-mass may be related to the adequacy of nutrition (10,11). Franks *et al.* (11) used the nutritional restriction model to describe tumor growth, obtained nutrients by diffusion from the surroundings, and determined the birth and death of breast cancer cells by the concentration of nutrients. Their results showed that breast cancer with sufficient nutrition was more invasive and prone to ML growth. When nutrition is insufficient, breast cancer tends to grow along the ducts, presenting as NML.

Ko *et al.* (12) explored the morphological characteristics of triple-negative breast cancer [estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) negative] and found that 86% of triple-negative breast cancer exists in the form of mass, and is less manifested as non-mass lesions. Jiang *et al.* (13) showed that there was only a significant difference in histological grades between mass type and malignant NML (MNML), while those of ER, PR, HER2, P53, and Ki-67 did not exhibit significant differences. Therefore, further study is still needed on the formation mechanism of the morphological features of ML and NML US images.

Data-independent acquisition (DIA) is a major advance in protein quantification, enabling high-throughput quantitative proteomics (14). With the help of spectral libraries from previous DIA experiments or auxiliary data-dependent acquisition (DDA) data, DIA analysis can obtain the same repeatability and accuracy as parallel reaction monitoring (PRM) identification and quantification, except for low-abundance peptides that are blocked by strong signals (15). Non-targeted DIA has shown great potential in comprehensively revealing and validating the predictive and prognostic candidate biomarkers for various diseases, such as cancer, liver failure, and breast cancer (16). Numerous studies have shown that the screening of breast cancer proteomics information plays an important role in the classification of functional subtypes and staging of breast cancer, revealing the mechanism of breast cancer, and exploring the metastatic and invasive properties of breast cancer (17,18). In addition, some studies have shown that proteomics can also be applied for the prediction of breast cancer recurrence, the assessment and reduction of cancer cell resistance, and the selection and monitoring of the most appropriate breast cancer treatment programs as well as other prognostic and therapeutic studies (19,20).

At present, further study on the formation mechanism of the morphological characteristics of ML and NML US images, especially malignant ML (MML) and NML, is still needed. In this study, the DIA method was employed to detect the differences between ML and NML proteomics, aiming to explore the formation mechanism of the morphological characteristics of ML and NML US images. Our findings provide a basis for the pathological study of the morphological characteristics of ML and NML in US images of breast lesions. We present the following article in accordance with the MDAR reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-6655/rc>).

### Highlight box

#### Key findings

- MP2K3 is the up-regulated differential expression protein in the MML/MNML and BML/BNML groups, which may be related to the ultrasonic morphological characteristics of breast lesions.

#### What is known and what is new?

- Current studies have shown that proteomics is significantly different in different types of breast cancer and between breast cancer and adjacent normal tissues.
- In this study, the proteomics of mass-like and non-mass-like breast lesions was significantly different. The tumor necrosis factor signaling pathway may be associated with the ultrasonic morphological characteristics of breast lesions.

#### What is the implication, and what should change now?

- Further exploration of the specific mechanism of the tumor necrosis factor signaling pathway in the formation of malignant ML and NML ultrasonic morphology is needed.

## Methods

### Patients

The experimental samples were derived from 42 cases of ML and NML breast lesions treated by vacuum-assisted breast biopsy or tumor resection in the US diagnosis and general surgery departments of our hospital from January to August 2021, including 10 cases of MML, 10 cases of benign ML (BML), 10 cases of MNML, and seven cases of benign NML (tissue size: 300–500 mg per case).

The patients included in the study were 18–70-year-old women whose conventional breast US examinations showed ML and NML. Also, the pathological results of the patients were clear, and all patients signed the informed consent. This study was approved by the ethics committee of the First Medical Center of PLA General Hospital (No. S2021-683-01). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

### Sample collection

During vacuum-assisted breast biopsy and treatment, benign NML or ML lesion tissues were taken directly. After breast cancer was confirmed by frozen section pathology, MNML or ML tumor tissues and adjacent tissues were collected directly during tumor resection in breast surgery, and the proportion of non-necrotic tumor tissues was >70%. The tissue size was 300–500 mg. The specimens were placed in a labeled frozen tube and quickly frozen in liquid nitrogen. The specimens were then stored in a refrigerator at  $-80^{\circ}\text{C}$  within 20 minutes.

### Protein extraction and enzymolysis

The samples were chopped with liquid nitrogen, lysed in lysis buffer containing 50 mM ammonium bicarbonate ( $\text{NH}_4\text{HCO}_3$ ) pH 7.4, 10 mM magnesium chloride ( $\text{MgCl}_2$ ), 7 M urea, and 2 M thiourea, and then sonicated on ice for 5 min. The lysate was then centrifuged at 12,000 g at  $4^{\circ}\text{C}$  for 15 min, and the supernatant was transferred to a clean tube. The protein concentration was determined using a Bradford protein assay. Each sample was reduced with 10 mM dithiothreitol (DTT) at  $56^{\circ}\text{C}$  for 1 h and then alkylated with enough iodoacetamide in the dark at room temperature for 1 h. The protein was digested with trypsin (Promega, Beijing) at a substrate ratio of 1:50. After digestion at  $37^{\circ}\text{C}$  for 16 h, some peptides in the sample were uniformly mixed. The digestion solution was

lyophilized and the peptide was redissolved with 25 mM  $\text{NH}_4\text{HCO}_3$  30  $\mu\text{L}$  per tube.

### High-performance liquid chromatographic separation

A C18 column (Waters BEH, China, C18 4.6 $\times$ 250 mm, 5  $\mu\text{m}$ ) and Rigol (China) L3000 HPLC column were used. The column temperature was  $50^{\circ}\text{C}$ , and the mobile phases A (2% acetonitrile, adjusted pH to 10.0 with ammonium hydroxide) and B (98% acetonitrile, adjusted pH to 10.0 with ammonium hydroxide) were applied. Ammonium hydroxide regulated pH to 10.0 gradient elution. The solvent gradient was as follows: 3% B, 5 min; 3–8% B, 0.1 min; 8–18% B, 11.9 min; 18–32% B, 11 min; 32–45% B, 7 min; 45–80% B, 3 min; 80% B, 5 min; and 80–5%, 0.1 min, 5% B, 6.9 min. The eluent was monitored at UV214 nm and collected at a rate of one tube per minute. Finally, six components were synthesized and all components were dried under vacuum and reconstituted in 0.1% (v/v) formic acid (FA) water. 0.2  $\mu\text{L}$  of standard peptide was added to the distilled sample for subsequent analysis.

### Liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) analysis—DDA mode

Proteomics analysis was performed using a U3000 UHPLC system (Thermo Fisher, Beijing) and an Orbitrap fusion mass spectrometer (Thermo Fisher, Beijing) in DDA mode. A total of 1  $\mu\text{g}$  of total peptide was extracted from the sample extracted with 0.1% formic acid (FA) and injected into a self-made C18 Nano-Trap column (2 cm  $\times$  100  $\mu\text{m}$ , 3  $\mu\text{m}$ ). The analytical column (25 cm  $\times$  75  $\mu\text{m}$ , 100 Å) was used to separate the peptides. The eluent B (0.08% FA in 80% acetonitrile (ACN), 20% water) and eluent A (0.1% FA) were linearly graded in the range of 0–100% for 120 min at a flow rate of 350 nL/min. The detailed solvent gradient was as follows: 0–4% B, 8 min; 4–10% B, 11 min; 10–25% B, 88 min; 25–50% B, 98 min; 50–99% B, 102 min; 99–0% B.

### LC-MS/MS analysis—DIA mode

A 100 mg sample was reconstructed in 0.1% FA, mixed with 0.2  $\mu\text{L}$  standard peptide [indexed retention time, (IRT) kit, Biognosys, Beijing], and entered into a U3000U HPLC system (Thermo Fisher) for DIA using an Orbitrap fusion mass spectrometer (Thermo Fisher). The liquid phase conditions were the same as those used for DDA. For DIA acquisition, the an intact (ms1) resolution was set to 120,000

**Table 1** Sample protein concentration

Sample name	Concentration (µg/µL)	Volume (µL)	Overall amount (µg)	Sample level
A1	1.62	700	1,134.89	A1
A2	4.43	700	3,099.89	A1
A3	8.92	700	6,240.85	A1
A4	2.10	500	1,049.58	A1
A5	1.16	500	579.76	A1
A6	3.14	700	2,197.65	A1
A7	6.38	700	4,467.97	A1
A8	3.49	700	2,444.32	A1
A9	1.19	700	829.52	A1
A10	3.72	700	2,603.40	A1
B1	1.89	700	1,321.37	A1
B2	4.52	700	3,167.44	A1
B3	3.45	700	2,417.43	A1
B4	4.60	700	3,223.26	A1
B5	2.55	700	1,786.52	A1
B6	1.06	700	742.52	A1
B7	1.11	700	776.64	A1
B8	1.90	700	1,333.06	A1
B9	0.93	700	648.11	A1
B10	1.90	700	1,333.06	A1
C1	1.43	700	1,000.26	A1
C2	2.81	700	1,969.56	A1
C3	1.40	700	980.39	A1
C4	2.53	700	1,768.28	A1
C5	3.48	700	2,438.93	A1
C6	1.83	700	1,282.83	A1
C7	1.58	700	1,106.50	A1
C8	7.90	700	5,528.30	A1
C9	2.72	500	1,359.11	A1
C10	1.72	500	859.94	A1
D1	1.84	700	1,290.49	A1
D2	1.24	700	868.96	A1
D3	1.02	700	714.76	A1
D4	2.46	700	1,718.64	A1
D5	2.08	700	1,457.08	A1
D6	1.11	700	779.53	A1
D7	2.54	700	1,777.39	A1

and the fragmented (ms2) resolution was set to 30,000. The M/z range was 350–1,350 m/z with a variable of 60 cycles. The full scan automatic gain control (AGC) target was set at  $4 \times 10^6$ , and the injection time was 50 ms. DIA was set to 35% normalized collision energy (NCE) with a target value of  $1 \times 10^6$  and a maximum injection time AUTO to enable the mass spectrometer to always operate in parallel ion filling and detection mode.

### *LC-MS/MS DIA data analysis*

For different comparison groups, the fold change (FC) and P value of each comparison method were analyzed and calculated, and the differential proteins were screened according to the following screening rules: FC >1.2 or FC <1/1.2, P < 0.05. The differences were listed in tables, and a volcano map was created using the Msstats R package.

Using the Homo sapiens database, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) networks analyses were performed to summarize and explain the functional localization and metabolic pathways of differentially expressed proteins in MML and MNML and BML and benign NML (BNML).

## **Results**

### *Analysis of the protein concentration of all samples*

Before DIA proteomics quantitative detection of NML and ML, we measured the sample tissue and extracted the protein concentration. The results are shown in *Table 1*. The tissue proteins of each sample reached the A1 standard, that is, the gel map was clear, the bands were rich, and there was no high abundance. Furthermore, 10 µg of each sample was taken for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The electrophoretic band is good and meets the requirements of the experiment, so the follow-up analysis can be continued.

### *Functional categorization/classification and pathway analysis of differentially expressed proteins*

The study subjects were divided into two comparison groups: MML/MNML and BML/BNML. MML/MNML compared the protein expression profiles of 10 pairs of MML and MNML, and the BML/BNML group compared the protein expression profiles of 10 benign mass breast

lesions and seven benign non-mass breast lesions.

The DIA technique was used to quantify the proteins in the two comparison groups (FC >1.2 or FC <1/1.2, and P<0.05). In the MML/MNML group, there were 623 differentially expressed proteins, including 463 up-regulated proteins and 160 down-regulated proteins, such as Transforming growth factor beta 1 (TGF- $\beta$ 1), thrombospondin-1 (TSP1), Integrin Subunit Beta 5 (ITGB5), insulin-like growth factors (IGF1), dual specificity mitogen-activated protein kinase kinase 3 (MP2K3), and other proteins, which may be related to the formation of MML. In the BML/BNML group, there were 167 differentially expressed proteins, of which 78 were up-regulated and 89 were down-regulated (Table 2). Figure 1 shows a volcano plot of these proteins. The protein with statistically significant difference (FC >1.2 or FC <1/1.2, and P<0.05) was located in the upper right and upper left quadrants. The top 10 up-regulated and down-regulated proteins in the MML/MNML and BML/BNML groups

are shown in Tables 3-6.


To further explore the molecular biological functions of the differentially expressed proteins, we performed GO analysis on the differentially expressed proteins in each group. Taking P=0.05 as the critical value, Fisher's exact test was used to evaluate the significance level of protein enrichment in the GO entries. The top 10 proteins in terms of biological process (BP), cellular component (CC), and molecular function (MF) of MML/MNML (Figure 2A) and BML/BNML (Figure 2B) groups were listed. In the MML/MNML group, differential proteins were primarily expressed in the proteasome, cytoplasm, and cell membrane, mainly playing a role in vesicle-mediated transport, the immune system process, and the protein transport cell cycle, and participating in tumor immunity and transcription. In the BML/BNML group, the differential proteins were primarily expressed in ribosomes, lysosomes, and mitochondria, mainly playing a role in the combination of compounds, proteins, and DNA, and participating in carbohydrate metabolism.

In the MML/MNML group, 38 of the 271 pathways that up-regulated differential protein enrichment were statistically significant (P<0.05). Among the 123 pathways that down-regulated differential protein enrichment, 10 were statistically significant (P<0.05). The results of the BML/BNML group showed that 12 out of 138 pathways up-regulated differential protein enrichment were statistically significant (P<0.05). Among the 216 pathways

**Table 2** Differential protein statistics

Comparisons	Up-	Down-	All-
MML/MNML	463	160	623
BML/BNML	78	89	167

MML, malignant mass-like; MNML, malignant non-mass-like; BML, benign mass-like; BNML, benign non-mass-like.



**Figure 1** Quantitative volcano plot of differentially expressed proteins in each group. (A) The quantitative volcano plot of differentially expressed proteins in the MML/MNML group; (B) the quantitative volcano plot of differentially expressed proteins in the BML/BNML group. FC, fold change; MML, malignant mass-like; MNML, malignant non-mass-like; BML, benign mass-like; BNML, benign non-mass-like.



**Table 3** Some up-regulated proteins in MML/MNML

ID	Gene name	Description	FC	P value
EXOS8	<i>EXOSC8</i>	Exosome complex component RRP43	5.239119	0.038737
RAD1	<i>RAD1</i>	Cell cycle checkpoint protein RAD1	4.560509	0.002449
BAK	<i>BAK1</i>	Bcl-2 homologous antagonist/killer	4.309771	0.042191
REN1	<i>ATP6AP2</i>	Renin receptor	4.265214	0.021494
MDN1	<i>MDN1</i>	Midasin	4.166939	0.001236
PAF1	<i>PAF1</i>	RNA polymerase II-associated factor 1 homolog	4.161053	0.047368
CD53	<i>CD53</i>	Leukocyte surface antigen CD53	4.079058	0.012453
RM47	<i>MRPL47</i>	39S ribosomal protein L47, mitochondrial	3.894424	0.006753
PUS7	<i>PUS7</i>	Pseudouridylate synthase 7 homolog	3.872687	0.027459
HLA-H	<i>HLA-H</i>	Putative HLA class I histocompatibility antigen, alpha chain H	3.847482	0.024387

MML, malignant mass-like; MNML, malignant non-mass-like; FC, fold change; HLA, human leukocyte antigen.

**Table 4** Some down-regulated proteins in MML/MNML

ID	Gene name	Description	FC	P value
ATD3B	<i>ATAD3B</i>	ATPase family AAA domain-containing protein 3B	0.210834	0.022599
KREM	<i>KREMEN2</i>	Kremen protein 2	0.220546	0.009884
APOF	<i>APOF</i>	Apolipoprotein F	0.234497	0.025941
TSH3	<i>TSHZ3</i>	Teashirt homolog 3	0.285312	0.044328
ABCC8	<i>ABCC8</i>	ATP-binding cassette sub-family C member 8	0.287352	0.032497
HPT	<i>HP</i>	Haptoglobin	0.28974	0.019481
TTHY	<i>TTR</i>	Transthyretin	0.293492	0.004586
CBPB1	<i>CPB1</i>	Carboxypeptidase B	0.293832	0.006205
BBS7	<i>BBS7</i>	Bardet-Biedl syndrome 7 protein	0.302366	0.047709
UT14C	<i>UTP14C</i>	U3 small nucleolar RNA-associated protein 14 homolog C	0.304547	0.032968

MML, malignant mass-like; MNML, malignant non-mass-like; FC, fold change; AAA, ATPase associated with various cellular activities.

that down-regulated differential protein enrichment, 15 were statistically significant ( $P < 0.05$ ). The top 10 up- and down-regulated protein enrichment results in the MML/MNML (Figure 3A,3B) and BML/BNML (Figure 3C,3D) groups are shown. The up-regulated differential proteins were significantly enriched in the tumor necrosis factor (TNF) signaling pathway in both the MML/MNML and BML/BNML groups, suggesting that the TNF signaling pathway may have a certain correlation with the ultrasonic morphological characteristics of breast lesions.

The results also showed that the expressions of KS6A5, NFKB1, CASP3, MK09, MP2K4, MP2K3, MP2K6,

FADD, CASP8, MLKL, and PGAM5 were up-regulated in the MML/MNML group. In the BML/BNML group, the expressions of MMP9, TNFR6, and MP2K3 were up-regulated. The expression of MP2K3 was up-regulated in both MML/MNML and BML/BNML groups. The String database was used to analyze the differential proteins in the MML/MNML and BML/BNML groups, and a PPI network was constructed to explore the interaction between differential proteins. According to the degree of connectivity, the key proteins of the top 10 differentially expressed proteins in the MML/MNML and BML/BNML groups were screened out. The specific connection results

**Table 5** Some up-regulated proteins in BML/BNML

ID	Gene name	Description	FC	P value
BAHC1	<i>BAHCC1</i>	BAH and coiled-coil domain-containing protein 1	55.62595	0.042654
PLF4	<i>PF4</i>	Platelet factor 4	8.1197	0.044365
NGRN	<i>NGRN</i>	Neugrin	6.70711	0.044657
ITA2B	<i>ITGA2B</i>	Integrin alpha-IIb	5.987456	0.028433
CXCL7	<i>PPBP</i>	Platelet basic protein	5.318866	0.039697
HBD	<i>HBD</i>	Hemoglobin subunit delta	4.802102	0.045545
ITB3	<i>ITGB3</i>	Integrin beta-3	4.74663	0.014112
HBB	<i>HBB</i>	Hemoglobin subunit beta	4.624392	0.039199
ANCHR	<i>ZFYVE19</i>	Abscission/NoCut checkpoint regulator	4.494138	0.035925
HBAT	<i>HBQ1</i>	Hemoglobin subunit theta-1	4.128817	0.031052

BML, benign mass-like; BNML, benign non-mass-like; FC, fold change.

**Table 6** Some down-regulated proteins in BML/BNML

ID	Gene name	Description	FC	P value
PTH	<i>PTRH1</i>	Probable peptidyl-tRNA hydrolase	0.121963	0.031824
HMCS2	<i>HMGCS2</i>	Hydroxymethylglutaryl-CoA synthase, mitochondrial	0.127029	0.046378
MUCL1	<i>MUCL1</i>	Mucin-like protein 1	0.128836	0.048632
PNMT	<i>PNMT</i>	Phenylethanolamine N-methyltransferase	0.199291	0.041889
SULF2	<i>SULF2</i>	Extracellular sulfatase Sulf-2	0.230463	0.03582
PRC2C	<i>PRRC2C</i>	Protein PRRC2C	0.235124	0.027068
YTDC1	<i>YTHDC1</i>	YTH domain-containing protein 1	0.244612	0.031507
GPKOW	<i>GPKOW</i>	G-patch domain and KOW motifs-containing protein	0.249811	0.040969
RPC4	<i>POLR3D</i>	DNA-directed RNA polymerase III subunit RPC4	0.255658	0.024292
PLCC	<i>AGPAT3</i>	1-acyl-sn-glycerol-3-phosphate acyltransferase gamma	0.258439	0.008054


BML, benign mass-like; BNML, benign non-mass-like; FC, fold change.

of the top 10 differentially expressed key proteins in the MML/MNML and BML/BNML groups were shown in *Figure 4A* and *Figure 4B*.

## Discussion

ML and NML are US morphological types of breast diseases. Previous studies have shown that the formation of ML and NML may be related to nutritional status, invasiveness, and other factors (10,11). However, many molecular participants and mechanisms behind the morphological formation of US images are still unclear.

The progress of biomedical research is expected to uncover new molecular discoveries of ML and NML breast lesions. Clinical proteomics is currently undergoing rapid advances in technologies that are expected to provide new means of improving the early diagnosis, stratification, and treatment response to breast lesions. In this study, DIA-based quantitative proteomics was applied to study the histological reasons for the morphological differences between NML and ML, so as to explore the formation mechanism of ML or NML that may affect the ultrasonic morphology of breast lesions. Numerous significantly differentially expressed proteins were identified between the MML/



**Figure 2** The GO analyses results of the MML/MNML group (A) and the BML/BNML group (B). GO, Gene Ontology; MML, malignant mass-like; MNML, malignant non-mass-like; BML, benign mass-like; BNML, benign non-mass-like.

MNML and BML/BNML groups.


DIA proteomics was performed in 20 cases of ML and NML breast cancers and 17 cases of ML and NML benign lesions. The results showed that 623 and 167 proteins were significantly different in MML/MNML and BML/BNML groups, respectively ( $P < 0.05$ ). Previous studies have shown that there are significant differences in the biomarkers between MML and MNML (10,11). To further explore the functions of the differential proteins, GO, KEGG, and PPI analyses were performed on the MML/MNML and BML/BNML groups, respectively.

The TNF signaling pathway is involved in the immune response of several protein families and plays a key role in innate and acquired immunity (20,21). TNF- $\alpha$  has been found to induce epithelial-mesenchymal transformation (EMT) in multiple breast cancer cell lines, transforming cells into mesenchymal cell phenotypes and increasing the number of stem cells (22). It has also been found to induce EMT in several breast cancer cell lines, leading to the transformation of cells to the mesenchymal cell phenotype and an increased number of stem cells (22). In


this study, it was shown that in the MML/MNML group, the up-regulated differential proteins of the TNF signaling pathway were enriched in both the MML/MNML and BML/BNML groups, suggesting that the TNF signaling pathway may be related to the ultrasonic morphological changes of breast lesions. In the MML/MNML group, the KS6A5, NFKB1, CASP3, MK09, MP2K4, MP2K3, MP2K6, FADD, CASP8, MLKL, and PGAM5 up-regulated proteins may be involved in biological processes such as apoptosis, necroptosis, intracellular signal transduction, and cell degeneration of MML. In the BML/BNML group, the MMP9, TNR6, and MP2K3 differential proteins were up-regulated in the TNF signaling pathway, suggesting that MMP9, TNR6, and MP2K3 may be involved in BML intracellular signal transduction and cell survival and other biological processes.

The DIA results in this study showed that MP2K3 protein expression was significantly up-regulated in the TNF signaling pathway of the MML/MNML and BML/BNML groups, suggesting that MP2K3 may be related to the formation of the ultrasonic morphology of breast





**Figure 3** The top 10 up- and down-regulated protein enrichment KEGG pathways in the MML/MNML (A,B) and BML/BNML (C,D) groups. KEGG, Kyoto Encyclopedia of Genes and Genomes; TNF, tumor necrosis factor; MML, malignant mass-like; MNML, malignant non-mass-like; BML, benign mass-like; BNML, benign non-mass-like.



**Figure 4** The specific linkage results of the top 10 key proteins in the PPI network in the MML/MNML (A) and the BML/BNML (B) groups. PPI, protein-protein interaction; MML, malignant mass-like; MNML, malignant non-mass-like; BML, benign mass-like; BNML, benign non-mass-like.

lesions. MP2K3 is a bispecific kinase belonging to the MAP kinase family. It is activated by inflammation and endoplasmic reticulum stress, phosphorylates and activates the 38 mitogen-activated protein kinase axis, and participates in cell growth, differentiation, apoptosis, movement, and inflammation (23). In addition, studies have shown that MP2K3 may also be involved in the EMT of primary tumor cells (24,25). Peng *et al.* (25) confirmed that MP2K3 knockout can inhibit the growth, proliferation, invasion, and migration of cervical cancer *in vitro* and *in vivo*. Xie *et al.* (26) used MP2K3 inhibitors to inhibit esophageal cancer *in vitro* and *in vivo*. Jia *et al.* (27) found that MP2K3 has pro-aging activity and is down-regulated in human breast cancer compared with normal human mammary epithelial cells. In the breast cancer model of MacNeil *et al.* (28), activated MP2K3 significantly limited tumor growth *in vivo* and *in vitro* cell line expression systems, while impaired MP2K3 signaling significantly promoted tumor growth. In this study, the expression of MP2K3 was not only up-regulated in MML compared to MNML but was also up-regulated in BML relative to BNML, suggesting that MP2K3 may be related to the ultrasonic morphology of breast lesions.

We also analyzed the functions of proteins with significant expression differences in the MML/MNML group, screened out some interesting proteins that may have important clinical significance, and preliminarily explored their possible mechanisms in the formation of MML. The expressions of EIF4A3, 2AAA, RPS3, PP2AA, DYNC1H1, TGF- $\beta$ 1, TSP1, IGF1, and ITGB5 protein in MML was higher than that in MNML, suggesting that these proteins may be related to the ultrasonic morphological characteristics of breast cancer. Thus, further exploration of the specific mechanism of these proteins in the formation of MML and MNML ultrasonic morphology is needed.

This study still has some limitations that should be noted. Firstly, this study compared the proteomic differences between mass and non-mass breast lesions; however, the sample size was not sufficient, and the proteomic results need to be further verified. Second, as a prospective study, there are still some pathological types that were not involved. Moreover, the selection of breast lesions was closely related to the experience of the operator, and the different parts of the same lesion were related to the final diagnosis results, with a certain degree of subjectivity. Besides, our study lacked further validation of MP2K3 and TNF signaling pathways. In the following studies, we intend to further verify this with western blot.

In addition, in the next research, we can also add studies on the correlation between breast cancer histopathological factors and TNF signaling pathway and MP2K3.

## Conclusions

Our results illustrated that the TNF signaling pathway may be related to the ultrasonic morphological characteristics of breast lesions. MP2K3 is an up-regulated differentially expressed protein in the MML/MNML and BML/BNML groups, which may be related to the ultrasonic morphological characteristics of breast lesions. However, further studies are needed to explore the underlying biological mechanisms of MP2K3 and TNF signaling in the US morphology of breast lesions.

## Acknowledgments

**Funding:** This work was supported by the National Natural Science Foundation of China (No. 82071925), the Military Health Special Research Project (No. 22BJZ23), the National Key Research and Development Program of China (No. 2019YFC0118800), and the Equipment Comprehensive Research Project (No. LB20211A010011).

## Footnote

**Reporting Checklist:** The authors have completed the MDAR reporting checklist. Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-6655/rc>

**Data Sharing Statement:** Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-6655/dss>

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-6655/coif>). The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was approved by the ethics committee of the First Medical Center of PLA General Hospital (No. S2021-683-01). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). All patients signed the informed consent.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Barzaman K, Karami J, Zarei Z, et al. Breast cancer: Biology, biomarkers, and treatments. *Int Immunopharmacol* 2020;84:106535.
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71:209-49.
3. Li T, Mello-Thoms C, Brennan PC. Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence. *Breast Cancer Res Treat* 2016;159:395-406.
4. Brem RF, Lenihan MJ, Lieberman J, et al. Screening breast ultrasound: past, present, and future. *AJR Am J Roentgenol* 2015;204:234-40.
5. Wang ZL, Li N, Li M, et al. Non-mass-like lesions on breast ultrasound: classification and correlation with histology. *Radiol Med* 2015;120:905-10.
6. Wang ZL, Li Y, Wan WB, et al. Shear-Wave Elastography: Could it be Helpful for the Diagnosis of Non-Mass-Like Breast Lesions? *Ultrasound Med Biol* 2017;43:83-90.
7. Zhang W, Xiao X, Xu X, et al. Non-Mass Breast Lesions on Ultrasound: Feature Exploration and Multimode Ultrasonic Diagnosis. *Ultrasound Med Biol* 2018;44:1703-11.
8. Li J, Yuan M, Yang L, et al. Correlation of contrast-enhanced ultrasound features with prognostic factors in invasive ductal carcinomas of the breast. *Jpn J Radiol* 2020;38:960-7.
9. Kim KE, Park H, Bae SH, et al. Usefulness of using additional ultrasonic dissection device in breast cancer surgery: a retrospective cohort study. *Gland Surg* 2021;10:3181-7.
10. Morishima I, Ueno E, Tohno E, et al. Ultrasonic diagnosis of non-mass image-forming breast cancer. In: Ueno E, Shiina T, Kubota M, et al. editors. *Research and Development in Breast Ultrasound*. Tokyo, Japan: Springer, 2005:127-34.
11. Franks SJ, Byrne HM, Mudhar HS, et al. Mathematical modelling of comedo ductal carcinoma in situ of the breast. *Math Med Biol* 2003;20:277-308.
12. Ko KH, Jung HK, Kim SJ, et al. Potential role of shear-wave ultrasound elastography for the differential diagnosis of breast non-mass lesions: preliminary report. *Eur Radiol* 2014;24:305-11.
13. Jiang L, Zhou Y, Wang Z, et al. Is there different correlation with prognostic factors between "non-mass" and "mass" type invasive ductal breast cancers? *Eur J Radiol* 2013;82:1404-9.
14. Neagu AN, Whitham D, Buonanno E, et al. Proteomics and its applications in breast cancer. *Am J Cancer Res* 2021;11:4006-49.
15. Hu A, Noble WS, Wolf-Yadlin A. Technical advances in proteomics: new developments in data-independent acquisition. *F1000Res* 2016;5:eF1000 Faculty Rev-419.
16. Lin Y, Lin L, Fu F, et al. Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancer. *Breast Cancer Res Treat* 2021;185:39-52.
17. Wang R, Yin Y, Zhu ZJ. Advancing untargeted metabolomics using data-independent acquisition mass spectrometry technology. *Anal Bioanal Chem* 2019;411:4349-57.
18. Chae YK, Gonzalez-Angulo AM. Implications of functional proteomics in breast cancer. *Oncologist* 2014;19:328-35.
19. Yanovich G, Agmon H, Harel M, et al. Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification. *Cancer Res* 2018;78:6001-10.
20. Stöhr D, Jeltsch A, Rehm M. TRAIL receptor signaling: From the basics of canonical signal transduction toward its entanglement with ER stress and the unfolded protein response. *Int Rev Cell Mol Biol* 2020;351:57-99.
21. Park YH, Jeong MS, Jang SB. Structural insights of homotypic interaction domains in the ligand-receptor signal transduction of tumor necrosis factor (TNF). *BMB Rep* 2016;49:159-66.
22. Bhatt AB, Patel S, Matossian MD, et al. Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling. *Biomolecules* 2021;11:183.
23. Kanda T, Sasaki-Tanaka R, Masuzaki R, et al. Knockdown of Mitogen-Activated Protein Kinase Kinase 3 Negatively Regulates Hepatitis A Virus Replication. *Int J Mol Sci* 2021;22:7420.
24. Bhowmick NA, Zent R, Ghiassi M, et al. Integrin beta 1 signaling is necessary for transforming growth factor-beta

- activation of p38MAPK and epithelial plasticity. *J Biol Chem* 2001;276:46707-13.
25. Peng R, Cheng X, Zhang Y, et al. miR-214 down-regulates MKK3 and suppresses malignant phenotypes of cervical cancer cells. *Gene* 2020;724:144146.
  26. Xie X, Liu K, Liu F, et al. Gossypetin is a novel MKK3 and MKK6 inhibitor that suppresses esophageal cancer growth in vitro and in vivo. *Cancer Lett* 2019;442:126-36.
  27. Jia M, Souchelnytskyi N, Hellman U, et al. Proteome

**Cite this article as:** Li SY, Wang B, Jiang Y, Li J, Liu G, Wang ZL. Proteomics comparison between mass-like and non-mass-like breast lesions. *Ann Transl Med* 2023;11(2):85. doi: 10.21037/atm-22-6655

- profiling of immortalization-to-senescence transition of human breast epithelial cells identified MP2K3 as a senescence-promoting protein which is downregulated in human breast cancer. *Proteomics Clin Appl* 2010;4:816-28.
28. MacNeil AJ, Jiao SC, McEachern LA, et al. MAPK kinase 3 is a tumor suppressor with reduced copy number in breast cancer. *Cancer Res* 2014;74:162-72.

(English Language Editor: A. Kassem)